La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George F. Tidmarsh purchased 19,000 shares of the stock on the open market in a transaction that occurred on Wednesday, July 23rd. The stock was purchased at an average cost of $10.50 per share, for a total transaction of $199,500.00. Following the purchase, the chief executive officer now directly owns 1,410,086 shares of the company’s stock, valued at approximately $14,805,903. The acquisition was disclosed in a legal filing with the SEC, which is available at this link.
Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at 11.26 on Friday. La Jolla Pharmaceutical Company has a 52 week low of $0.16 and a 52 week high of $19.50. The stock’s 50-day moving average is $9.5 and its 200-day moving average is $9.32. The company’s market cap is $88.6 million.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) last posted its quarterly earnings results on Friday, May 2nd. The company reported ($0.93) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.91) by $0.02. On average, analysts predict that La Jolla Pharmaceutical Company will post $-3.25 earnings per share for the current fiscal year.
A number of analysts have recently weighed in on LJPC shares. Analysts at Wedbush reiterated a “buy” rating on shares of La Jolla Pharmaceutical Company in a research note on Tuesday, July 15th. Separately, analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $34.00 to $38.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. Finally, analysts at Zacks downgraded shares of La Jolla Pharmaceutical Company to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $9.70 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. La Jolla Pharmaceutical Company has an average rating of “Buy” and an average price target of $27.14.
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.